Tune Therapeutics, a leading epigenome editing company, has secured over $175 million in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures, and Hevolution Foundation. The funding will accelerate the development of the company’s clinical-stage Hepatitis B program, Tune-401, and support the advancement of its gene and cell therapy programs.
The investment marks a significant milestone for Tune Therapeutics, which has made progress in developing its novel epigenome editing platform, TEMPO. The platform has shown promise in treating chronic diseases, including Hepatitis B, which affects over 250 million people worldwide.
Tune-401, the company’s lead program, is a first-in-class epigenetic silencer for chronic Hepatitis B. It utilizes the TEMPO platform to silence viral intDNA and cccDNA necessary for sustained HBV infection. The funding will enable Tune Therapeutics to further develop Tune-401 and expand its pipeline of gene and cell therapy programs.
The investment from prominent investors, including Reed Jobs of Yosemite and William Greene of Hevolution Foundation, demonstrates confidence in Tune Therapeutics’ approach and the potential of epigenome editing as a therapeutic modality. The company’s co-founder and president, Akira Matsuno, stated that the funding will enable the development of new therapies for common and chronic diseases.
Tune Therapeutics aims to bring gene, cell, and regenerative therapies into a new era of human medicine using its powerful and innovative TEMPO platform. With the latest investment, the company is well-positioned to advance its pipeline and expand its reach in the field of epigenome editing.
Source: https://finance.yahoo.com/news/tune-therapeutics-completes-over-175m-010000116.html